Ovoca Bio is a clinical-stage biopharmaceutical company with a focus on women’s health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire. The Society for Women’s Health Research estimates that about one in ten premenopausal women suffer from HSDD, making it one of the most common female sexual problems. Founded and incorporated in Ireland, Ovoca Bio currently operates in Ireland, the UK, and Russia, and is listed on AIM and Euronext Growth in London and Dublin.
